RxDoctor Payments Data

Thomas Weyburn, DO

Medical Oncology · Crystal Lake, ILNPI 1487636478

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $656 of the $1,059 with a category attached, or 61.9%. Pharmacosmos Therapeutics Inc. accounts for 61.9% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2021 at $667 and has fallen 74.0% since, to $174 in 2025. That places this record below the midpoint for medical oncology clinicians in IL, where the typical reported total is $1,059.

$1,059in general payments, 2019–2025

Across 11 payments — averaging $96.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pharmacosmos Therapeutics Inc.$656
  • AbbVie$156
  • Stryker$131
  • Merck$29
  • Tempus AI, Inc$28
  • Exelixis Inc.$18
  • plus $42 from 3 others
$38,306in research payments, 2019–2025

Across 50 payments — averaging $766.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$38K

What the payments were for

  • Speaking & faculty fees$65662%
  • Food & beverage$31430%
  • Education$908%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,059 in reported general payments places this provider in the 50th percentile of 144 medical oncology providers in Illinois.

See all medical oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$190,319
Medicare patients
661
Services billed
1,681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban21$22,612
Anastrozole72$1,227
Tamoxifen Citrate32$659
Letrozole13$297
Dexamethasone12$233
Hydroxyurea15$201
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen12$155
Gabapentin12$146
Duloxetine Hcl13$71

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$22,61221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 144 medical oncology providers in Illinois.

Other medical oncology in Crystal Lake

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →